BRD2 and cutaneous melanoma: As BETi efficiently targeted ErbB3 expression in response to BRAFi/MEKi, we examined the correlation between BRD/BET expression and ErbB3 levels/phosphorylation in BRAF V600E/K-mutant cutaneous melanoma.34 In TCGA datasets, BRD2 and BRD4 levels were significantly correlated with ERBB3 gene and protein expression levels in BRAF-mutant melanoma patients (Fig. 3a, b, and Supplementary Fig. 3A).